Liability related to sale of future royalties, net as of December 31, 2024

$

542,212

Royalty payments to Royalty Pharma

(38,478

)

Interest expense related to sale of future royalties

54,964

Amortization of issuance costs related to sale of future royalties

458

Liability related to sale of future royalties, net as of September 30, 2025

$

559,156

Less: Current portion (1)

(13,974

)

Liability related to sale of future royalties, net as of September 30, 2025 – Non-current

$

545,182